<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957554</url>
  </required_header>
  <id_info>
    <org_study_id>IRBAM_R_04219</org_study_id>
    <nct_id>NCT00957554</nct_id>
  </id_info>
  <brief_title>Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy</brief_title>
  <acronym>I-ADD</acronym>
  <official_title>Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate that the antihypertensive efficacy of the fixed combination
      irbesartan/amlodipine 300/5 mg is superior to that of irbesartan 300 mg monotherapy in
      lowering systolic blood pressure (SBP) as measured by home blood pressure measurement (HBPM)
      after 10 weeks of treatment (W10)

      Secondary Objective:

        -  To compare the antihypertensive efficacy of the fixed combination irbesartan/amlodipine
           300/5 mg with that of irbesartan 300 mg monotherapy after 10 weeks of treatment (W10)

        -  To compare the antihypertensive efficacy of the fixed combination therapy
           irbesartan/amlodipine 150/5 mg with that of irbesartan 150 mg monotherapy after 5 weeks
           of treatment (W5)

        -  To examine in each treatment group the change from week 5 to week 10 in SBP and
           diastolic blood pressure (DBP) assessed by HBPM and by office blood pressure measurement
           (OBPM)

        -  To determine the incidence and severity of adverse events
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean home systolic blood pressure</measure>
    <time_frame>At randomisation and week 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean office blood pressure</measure>
    <time_frame>At randomisation, week 5 and week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean home diastolic blood pressure</measure>
    <time_frame>At randomisation, week 5 and week 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">435</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>irbesartan/amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>irbesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan/amlodipine</intervention_name>
    <description>Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily</description>
    <arm_group_label>irbesartan/amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan</intervention_name>
    <description>Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily</description>
    <arm_group_label>irbesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Established essential hypertension

          -  Treated with irbesartan 150 mg monotherapy for at least 4 weeks

          -  With uncontrolled BP defined as mean SBP = or &gt; 145 mmHg assessed by OBPM

          -  Signed written inform consent obtained prior to inclusion in the study

        Randomisation Criteria:

          -  Mean SBP = or &gt; 135 mmHg assessed by HBPM

          -  Good compliance with the HBPM protocol defined as at least 12 correct measurements
             performed over the last 6 days of the first period of measurements

          -  Creatinine clearance = or &gt; 30 ml/min determined ny Cockroft formula

        Exclusion criteria:

          -  Mean SBP = or &gt; 180 mmHg and/or mean DBP = or &gt; 110 mmHg measured at doctor's office
             at Visit 1

          -  Known or suspected causes of secondary hypertension

          -  Patients with bilateral artery stenosis, renal artery stenosis in a solitary kidney,
             renal transplant or only has one functioning kidney

          -  Know contraindications or hypersensitivity to either amlodipine or irbesartan or to
             the combination or history of angioedema related to the administration of an
             angiotensin II receptor antagonist or any combination of the drugs used

          -  Know type 1 diabetes

          -  Know severe hepatic impairment alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) &gt; 5 times the upper limit of normal or history of hepatic
             encephalopathy, esophageal varices, or portocaval shunt

          -  Know severe renal impairment (creatinine clearance &lt; 30 ml/mn)

          -  Concomitant use of any other antihypertensive treatment

          -  Administration of any other investigational drug within 30 days before inclusion

          -  Inability to obtain a valid automatic BP measurement recording

          -  Presence of any severe medical or psychological condition that, in the opinion of the
             investigator, indicate that participation in the study is not in the best interest of
             of the patient

          -  Presence of any other conditions (e.g.: geographical, social, etc) that would restrict
             or limit the patient participation for the duration of the study

          -  Pregnant or breast feeding women

          -  Women of childbearing potential unable or unwilling to use an acceptable method to
             avoid pregnancy for the entire study period

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Genes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07605</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07602</name>
      <address>
        <city>Caxias do Sul</city>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07604</name>
      <address>
        <city>Maceió</city>
        <zip>57051-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07601</name>
      <address>
        <city>Sorocaba</city>
        <zip>18030-083</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 07603</name>
      <address>
        <city>São José do Rio Preto</city>
        <zip>15015-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 17001</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 17002</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 17003</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 32001</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 32002</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 32003</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 32004</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 32005</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48402</name>
      <address>
        <city>Guadalajara</city>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48406</name>
      <address>
        <city>Mexico</city>
        <zip>11340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48401</name>
      <address>
        <city>Mérida</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48403</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>72244</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48407</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48404</name>
      <address>
        <city>Torreon</city>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 48408</name>
      <address>
        <city>Zapopan</city>
        <zip>44210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50403</name>
      <address>
        <city>Casablanca</city>
        <zip>20000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50401</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50402</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50405</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50404</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 50406</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78805</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78804</name>
      <address>
        <city>La marsa</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78802</name>
      <address>
        <city>Menzel Bourguiba</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78813</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78815</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78801</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78812</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78803</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 78807</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 784-001</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 784-02</name>
      <address>
        <city>Dubai</city>
        <zip>4545</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 86201</name>
      <address>
        <city>Maracaibo</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Guatemala</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Tunisia</country>
    <country>United Arab Emirates</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Saudi Arabia</country>
  </removed_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>October 25, 2010</last_update_submitted>
  <last_update_submitted_qc>October 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

